REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
42 hedge funds and large institutions have $14M invested in REVIVA PHARMA HLDGS INC in 2024 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 10 increasing their positions, 8 reducing their positions, and 9 closing their positions.
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
70% more call options, than puts
Call options by funds: $2.79M | Put options by funds: $1.65M
27% more funds holding
Funds holding: 33 → 42 (+9)
25% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 8
0.67% less ownership
Funds ownership: 1.5% → 0.83% (-0.67%)
6% less capital invested
Capital invested by funds: $14.9M → $14M (-$927K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$500K |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$237K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$193K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$64.7K |
| 5 |
EGM
Engineers Gate Manager
New York
|
+$48.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$2.54M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$986K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$637K |
| 4 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$223K |
| 5 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$141K |
RVPH Hedge Fund Activity: Q4 2024 in Review
42 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q4 2024, worth a combined $14M — down 6.2% from $14.9M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RVPH positions and 9 closed out — a net gain of 9 holders — while 10 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $500K. The largest seller was Armistice Capital, cutting an estimated $2.54M.
- 42 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q4 2024, up from 33 in Q3 2024.
- Funds reported $14M of REVIVA PHARMA HLDGS INC stock for Q4 2024, down 6.2% quarter-over-quarter.
- 18 funds opened new REVIVA PHARMA HLDGS INC positions in Q4 2024 and 9 closed out, a net change of +9 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q4 2024 was Vanguard Group, an estimated $500K added.
- The largest REVIVA PHARMA HLDGS INC seller in Q4 2024 was Armistice Capital, an estimated $2.54M sold.
Based on aggregated 13F filings for Q4 2024.